# Benefit of IQP-VV-102 in Reducing Postprandial Glucose Level in Overweight Caucasian Subjects

> **NCT02541344** · PHASE3 · COMPLETED · sponsor: **InQpharm Group** · enrollment: 27 (estimated)

## Conditions studied

- Prediabetes
- Hyperglycemia

## Interventions

- **DEVICE:** Dose 1 of IQP-VV-102
- **DEVICE:** Dose 2 of IQP-VV-102
- **DEVICE:** Placebo

## Key facts

- **NCT ID:** NCT02541344
- **Lead sponsor:** InQpharm Group
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-06
- **Primary completion:** 2015-10
- **Final completion:** —
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2015-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02541344

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02541344, "Benefit of IQP-VV-102 in Reducing Postprandial Glucose Level in Overweight Caucasian Subjects". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02541344. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*